Emily Walsh Martin, PhD, spoke with Amber Freed, founder and CEO of SLC6A1 Connect, a patient organization focused on accelerating the development of therapies for SLC6A1 patients like her son Maxwell.

Development of a secretable frataxin for Friedrich’s ataxia with Dr. Dan DuBreuil
19:48

Member Minutes: Mark Deehan, PhD
06:28

Member Minutes: Chrissy Green
11:20